The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial.

Johannes M WellerThomas ZeyenNiklas SchäferChristina SchaubAnna-Laura PotthoffJoachim P SteinbachPeter HauClemens SeidelRoland GoldbrunnerGhazaleh TabatabaiHartmut VatterTheophilos TzaridisMatthias SchneiderUlrich Herrlinger

Published in: Journal of neuro-oncology (2023)

In contrast to AVAglio, glioblastoma gene expression subgroups were not associated with a differential OS benefit from first-line bevacizumab in the GLARIUS trial.

Keyphrases

gene expression
newly diagnosed
phase iii
study protocol
phase ii
clinical trial
metastatic colorectal cancer
dna methylation
magnetic resonance
randomized controlled trial
open label
computed tomography
magnetic resonance imaging
contrast enhanced